Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01312909 · ClinicalTrials.gov registry record · Phase 4

Smoking Cessation Study In Healthy Adolescent Smokers

A Phase 4 study, sponsored by Pfizer.

Completed
Registry status
Phase 4
Development phase
312
Enrollment target

NCT01312909 is a Phase 4 study that has completed, run by Pfizer. The registered enrollment target is 312 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01312909, a Phase 4 study, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 4
Development phase
312 participants
Enrollment target

Study Summary

The study is designed to see if varenicline combined with age appropriate (adolescent) smoking cessation counseling will help teens quit smoking.

Interventions

  • DRUG Placebo
  • DRUG Varenicline 1mg BID
  • DRUG Varenicline 0.5mg BID

Trial Details

FieldValue
Enrollment Target 312 participants
Start Date 2011-04
Est. Completion 2018-01
Phase Phase 4

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT01312909

The ClinicalTrials.gov registry entry for NCT01312909 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 312 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT01312909 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01312909 about?

NCT01312909 is a clinical study titled "Smoking Cessation Study In Healthy Adolescent Smokers". The study is designed to see if varenicline combined with age appropriate (adolescent) smoking cessation counseling will help teens quit smoking.

What is the current status of trial NCT01312909?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 312 participants. The study started on 2011-04. Estimated completion is 2018-01.

What interventions are being tested in trial NCT01312909?

The interventions under investigation include: Placebo (DRUG), Varenicline 1mg BID (DRUG), Varenicline 0.5mg BID (DRUG).

Who is sponsoring clinical trial NCT01312909?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.